drugset / Trial / NCT00575185

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

NCT00575185

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical diagnosis of primary infectious mononucleosis will be screened and those with laboratory-confirmed primary EBV infection will be enrolled.

Timeline

Start
2007-11
Primary completion
2009-07
Completion
2010-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Valomaciclovir Small molecule 2 g Oral